HB0424 expands and revises Maryland’s Prescription Drug Affordability Board (PDAB) framework to give the Board broader authority over prescription drug pricing. The bill changes the composition of the Prescription Drug Affordability Stakeholder Council by adding and adjusting appointed seats, including representation for rare disease patients, oncologists, and patient advocacy organizations. It also adds reporting requirements so the Board must evaluate and report on the effects of any upper payment limit on patient costs, premiums, pharmacy viability, formularies, provider-administered drugs, access in rural and underserved communities, 340B providers, and the biotechnology industry.
The bill also revises the rules governing upper payment limits. It clarifies criteria the Board must consider, adds protections for drugs in current shortage, bars the Board from applying upper payment limits to Medicare Part C and Part D reimbursement requirements or to pharmacy dispensing fees, and requires consultation with the Maryland Medical Assistance Program before any limit is applied to Medicaid. In addition, it authorizes the Board to reconsider an existing upper payment limit if a drug later becomes a current shortage, and it preserves the existing framework for Board action under approved plans of action.
A major feature of the bill is a new pathway for the Board to determine whether it is in the State’s best interest to extend upper payment limits beyond the existing government-purchase and public-program categories to all purchases and payor reimbursements of prescription drug products that create affordability challenges. If the Board makes that determination, it must establish a process for statewide upper payment limits, using the approved plan of action where appropriate and otherwise complying with the subtitle’s requirements. The bill excludes certain federal and preempted programs, including Medicare Part C and D, 340B purchases, and various federal health programs.
The bill’s impact on state law is to broaden the PDAB’s potential reach while adding procedural safeguards, reporting obligations, and carve-outs intended to address access, federal preemption, and program-specific concerns. It also creates a contingent future expansion: a second section authorizing statewide upper payment limits takes effect only if the Board sets upper payment limits on two drugs and each has been in effect for one year, with a sunset if that condition is not met by the statutory deadline. Overall, the legislation strengthens the State’s prescription drug affordability tools while trying to limit unintended consequences for patients, pharmacies, providers, and public programs.
The general sentiment reflected by the bill text is strongly supportive of lowering prescription drug costs, but with clear caution about implementation. The title and structure emphasize affordability and broader consumer protection, while the added reporting and consultation requirements show concern about real-world effects on access, shortages, and reimbursement. The main points of contention are likely the scope of the Board’s authority, the possibility of statewide upper payment limits, and the impact on rare disease drugs, 340B providers, pharmacies, Medicaid, and the biotechnology sector. The bill’s detailed exclusions and monitoring requirements suggest an effort to balance cost containment with concerns raised by providers, manufacturers, and patient advocates.
HB0424 amends Title 21, Subtitle 2C of the Health-General Article governing the Prescription Drug Affordability Board. It changes stakeholder council membership, expands the Board’s reporting duties, revises criteria and limits for upper payment limits, and creates a new mechanism for the Board to consider setting upper payment limits on all prescription drug purchases and payor reimbursements in the State, subject to federal-law carve-outs and procedural approvals. It also adds new definitions, including “current shortage,” and requires consultation with the Maryland Medical Assistance Program before any upper payment limit is applied to Medicaid.
The bill is framed as a prescription drug affordability measure and appears generally pro-consumer and pro-cost reduction. At the same time, the text shows substantial caution about access, shortages, and downstream effects on pharmacies, providers, and industry, indicating that supporters sought to expand affordability tools without ignoring operational risks. The absence of recorded committee discussion or votes in the provided context limits any more specific assessment of legislative sentiment.
The most notable areas of contention are the Board’s expanded authority to set upper payment limits statewide, the risk of shortages or access disruptions, and the bill’s effects on pharmacies, 340B entities, Medicaid, Medicare Part C and D, rare disease patients, and the biotechnology industry. The bill explicitly addresses concerns from patient advocates, rare disease communities, and providers by requiring additional reporting and consultation, while also limiting the Board’s reach in federally regulated or preempted areas. These provisions suggest that stakeholders likely disagreed over how far the State should go in regulating drug prices and how to balance affordability against access and market impacts.